PRQR vs. SCPH, PRLD, CAPR, GOSS, RIGL, RPTX, CRVO, ALIM, CTMX, and SKYE
Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include scPharmaceuticals (SCPH), Prelude Therapeutics (PRLD), Capricor Therapeutics (CAPR), Gossamer Bio (GOSS), Rigel Pharmaceuticals (RIGL), Repare Therapeutics (RPTX), CervoMed (CRVO), Alimera Sciences (ALIM), CytomX Therapeutics (CTMX), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical preparations" industry.
ProQR Therapeutics (NASDAQ:PRQR) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
In the previous week, scPharmaceuticals had 34 more articles in the media than ProQR Therapeutics. MarketBeat recorded 38 mentions for scPharmaceuticals and 4 mentions for ProQR Therapeutics. scPharmaceuticals' average media sentiment score of 0.23 beat ProQR Therapeutics' score of -0.15 indicating that scPharmaceuticals is being referred to more favorably in the news media.
ProQR Therapeutics received 169 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.24% of users gave scPharmaceuticals an outperform vote while only 61.86% of users gave ProQR Therapeutics an outperform vote.
ProQR Therapeutics has higher earnings, but lower revenue than scPharmaceuticals. ProQR Therapeutics is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ProQR Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.
32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 5.5% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ProQR Therapeutics has a net margin of -260.75% compared to scPharmaceuticals' net margin of -327.29%. ProQR Therapeutics' return on equity of -61.58% beat scPharmaceuticals' return on equity.
ProQR Therapeutics currently has a consensus price target of $3.38, suggesting a potential upside of 73.09%. scPharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 320.35%. Given scPharmaceuticals' higher possible upside, analysts plainly believe scPharmaceuticals is more favorable than ProQR Therapeutics.
Summary
ProQR Therapeutics beats scPharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get ProQR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProQR Therapeutics Competitors List
Related Companies and Tools
